These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

62 related items for PubMed ID: 2217479

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Prognostic factors of advanced prostatic carcinoma.
    Lukkarinen O, Lehikoinen K.
    Ann Chir Gynaecol Suppl; 1993; 206():9-13. PubMed ID: 8291878
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB.
    Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
    [No Abstract] [Full Text] [Related]

  • 30. [Cancer of the prostate: current status of chemotherapy].
    Bollak C, Bergerat JP, Jacquemin D.
    Bull Cancer; 1986; 73(1):61-4. PubMed ID: 3535934
    [Abstract] [Full Text] [Related]

  • 31. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA, Lange PH, Janknegt RA, Abbou CC, deGery A.
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [Abstract] [Full Text] [Related]

  • 32. New drugs in the management of advanced prostate cancer.
    Kelly WK.
    Cancer J; 2008 Apr; 14(1):10. PubMed ID: 18303476
    [No Abstract] [Full Text] [Related]

  • 33. [Significance of the karyopyknotic index in the course control of hormone-treated prostatic carcinoma].
    Funke PJ, Chiari R.
    Z Urol Nephrol; 1976 Jul; 69(7):501-5. PubMed ID: 998016
    [No Abstract] [Full Text] [Related]

  • 34. [The future of chemotherapy of prostatic cancer].
    Grillo-López AJ, Vélez-García E.
    Bol Asoc Med P R; 1975 Nov; 67(11):327-30. PubMed ID: 1060454
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. [Molecular target therapy].
    Tamura K.
    Nihon Rinsho; 2016 May 20; 74 Suppl 3():226-33. PubMed ID: 27344733
    [No Abstract] [Full Text] [Related]

  • 37. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience.
    Tirelli U.
    Br J Cancer; 2008 Oct 21; 99(8):1364; author reply 1365. PubMed ID: 18781182
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Biomarkers for prostate cancer: who will benefit from local treatment, who harbors occult systemic disease and who needs treatment at all?
    Citrin D, Camphausen KA.
    Biomark Med; 2013 Dec 21; 7(6):823-5. PubMed ID: 24266814
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.